Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Transfemoral Implant of Inovare® Transcatheter Valve

A legfontosabb adatok

Ki végzi
Braile Biomedica Ind. Com. e Repr. Ltda.
Hol
Brazília4 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
60 fő vett részt
Kezdés
2020. szept. 11.
Várható befejezés
2028. dec. 30.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • INOVARE® Transcatheter Valve, NexusCath Delivery System, Aureus Expandable Introducer, Balloon Catheter for Pre-Dilation and Compression Device (Crimper)
A regiszteradat frissítve
2024. január 11.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 31 feltétel megnézéseKevesebb

Ki vehet részt

  • Calcified degenerative aortic stenosis with valve area < 1.0 cm2 (or valve area index < 0.6 cm2/m2) and mean transvalvular gradient > 40 mmHg or aortic jet velocity > 4 m/s by echocardiogram
  • Multidisciplinary evaluation by the "Heart Team", composed of a cardiovascular surgeon, clinical cardiologist and hemodynamicist, which concludes that the patient has:; High surgical risk for aortic valve replacement, typically with an STS score of ≥ 8% (or logistic EuroSCORE ≥ 20%) or intermediate risk (STS of ≥ 3% and < 8%); Presence of porcelain aorta or hostile chest, as well as global clinical condition and comorbidities not fully addressed by the score STS; Presence of extreme frailty (5-meter walk test [5MWT], grip strength, activities of daily living (ADL), and albumin laboratory exam); Considerable chance of clinical benefit with the transcatheter procedure
  • Heart failure symptoms NYHA functional ≥ II
  • Aortic valve annulus with a mean diameter between 17.3 and 28.6 mm, documented by imaging method, suitable for positioning and accommodation of the Inovare® prosthesis, according to the judgment of an experienced hemodynamicist
  • Height of coronary ostia > 10 mm or presence of a coronary graft that prevents the occurrence of acute myocardial ischemia due to coronary occlusion after valve release
  • Femoral arterial access route considered adequate for the progression of the vascular introducer and prosthesis-balloon system, typically evaluated through multi-imaging methods that include, for example, conventional angiography and computed tomography
  • Patient has provided written informed consent to participate in the trial

Ki nem vehet részt

  • Hemodynamic instability requiring vasoactive drugs or circulatory support
  • Active peptic disease, gastrointestinal bleeding < 3 months, or previously diagnosed bleeding diathesis
  • Previous aortic or mitral valve procedure (surgical or by catheter, excluding aortic balloon valvuloplasty)
  • Clinical or biological signs of infection with systemic repercussions
  • Coronary artery disease requiring elective revascularization during or after the valve procedure
  • Evidence of myocardial infarction in an interval of less than one month
  • Recent stroke or transient ischemic attack (within the last 6 months)
  • Hypersensitivity or contraindication to the administration of heparin, ticlopidine or clopidogrel or to radiopaque contrast
  • Life expectancy less than 12 months due to non-cardiac disease or other comorbidities; Anatomical/morphological
  • Left ventricular ejection fraction < 30%
  • Chronic renal failure on dialysis or with serum creatinine levels > 3.0 mg/dL (265 µmol/L)
  • Acute renal failure with serum creatinine that has not yet returned to baseline levels
  • Anemia (hemoglobin < 10 g/dl), thrombocytopenia (< 100,000 cells/mm3) or hyperthrombocytosis (> 700,000 cells/mm3)
  • Clinic
  • Valve procedure with clinical need to be performed in a time of urgency or emergency (non-elective)
  • Endocarditis < 12 months
  • Need for chronic anticoagulation for other causes
  • Valve ring diameter less than or equal to 17.2 mm or greater than or equal to 28.7 mm
  • Iliofemoral access route, with extreme tortuosity or calcification or reduced luminal diameter (typically < 7 mm), which prevents safe progression of the arterial introducer and delivery system with the prosthesis, according to the judgment of the responsible physician
  • Presence of sessile and unstable atheromas in the ascending aorta and/or aortic arch detected by imaging methods
  • Obstructive hypertrophic cardiomyopathy or severe left ventricular outflow tract obstruction, with no possibility of balloon dilation
  • Moderate or severe aortic, mitral or tricuspid regurgitation
  • Non-calcified native valve
  • Evidence of an intracardiac mass (tumor, thrombus, or vegetation)

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Clinical trial to evaluate the early safety and efficacy of the transfemoral implant of Inovare® Transcatheter Valve for the treatment of patients with severe degenerative aortic stenosis and high surgical risk.

A vizsgálat csoportja

  • TAVI TRANSFEMORALA vizsgált kezelés

    Kezelés: INOVARE® Transcatheter Valve, NexusCath Delivery System, Aureus Expandable Introducer, Balloon Catheter for Pre-Dilation and Compression Device (Crimper)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Transfemoral Implant of Inovare® Transcatheter Valve - Clinical Trial of Feasibility and Safety and Efficacy Verification
A regiszteradat frissítve
2024. január 11.